Search
for
Sort by
Research 61–90 of 856
- Review of Hair Follicle Dermal Papilla cells as <i>in vitro</i> screening model for hair growth
- Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
- Emerging medication for the treatment of male hypogonadism
- Revisiting hyper- and hypo-androgenism by tandem mass spectrometry
- Polycystic Ovary Syndrome: A Common Reproductive and Metabolic Disorder Necessitating Early Recognition and Treatment
- Polycystic ovary syndrome and the differential diagnosis of hyperandrogenism
- Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute women
- Hyperandrogenism in polycystic ovary syndrome and adrenal hyperplasia: finding differences to make a specific diagnosis
- PCOS: Perspectives from a Pediatric Endocrinologist and a Pediatric Gynecologist
- Secondary amenorrhea
- Diagnosis and Management of Infertility due to Anovulation
- The Case of the Elusive Androgen
- Hormonal Therapy for Acne
- Skin as a Window to Endocrine Dysfunction: Dermatological and Metabolic Interactions in Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
- Period problems: disorders of menstruation in adolescents
- “Occult” ovarian Leydig cell tumor: when laboratory tells more than imaging
- Management of teenagers with polycystic ovarian syndrome
- MENSTRUAL DISORDERS IN ADOLESCENTS
- Adult polycystic ovary syndrome begins in childhood
- Polycystic ovary syndrome and insulin-resistant hyperinsulinemia
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
- New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men
- Hyperadrenocorticism in Ferrets
- The pediatric origins of polycystic ovary syndrome
- Hormonal contraceptives: pharmacology tailored to women's health
- How should postmenopausal androgen excess be evaluated?
- ANTIANDROGEN AND HORMONAL TREATMENT OF ACNE
- Repurposing existing drugs for COVID-19: an endocrinology perspective